| Literature DB >> 24705290 |
Albino Bacolla1, David N Cooper2, Karen M Vasquez3.
Abstract
Cancer genome sequence data provide an invaluable resource for inferring the key mechanisms by which mutations arise in cancer cells, favoring their survival, proliferation and invasiveness. Here we examine recent advances in understanding the molecular mechanisms responsible for the predominant type of genetic alteration found in cancer cells, somatic single base substitutions (SBSs). Cytosine methylation, demethylation and deamination, charge transfer reactions in DNA, DNA replication timing, chromatin status and altered DNA proofreading activities are all now known to contribute to the mechanisms leading to base substitution mutagenesis. We review current hypotheses as to the major processes that give rise to SBSs and evaluate their relative relevance in the light of knowledge acquired from cancer genome sequencing projects and the study of base modifications, DNA repair and lesion bypass. Although gene expression data on APOBEC3B enzymes provide support for a role in cancer mutagenesis through U:G mismatch intermediates, the enzyme preference for single-stranded DNA may limit its activity genome-wide. For SBSs at both CG:CG and YC:GR sites, we outline evidence for a prominent role of damage by charge transfer reactions that follow interactions of the DNA with reactive oxygen species (ROS) and other endogenous or exogenous electron-abstracting molecules.Entities:
Year: 2014 PMID: 24705290 PMCID: PMC3978516 DOI: 10.3390/genes5010108
Source DB: PubMed Journal: Genes (Basel) ISSN: 2073-4425 Impact factor: 4.096
Mutational signatures in cancer genomes.
| A. Main mutational signatures revealed from meta-analyses of cancer genomes | |||||
|---|---|---|---|---|---|
| Total number of mutations | Total number of cancer types | Major SBS signature (% cancer types) | Sequence context | References | |
| 4,938,362 | 30 | C:G→T:A (80%) | N | [ | |
| C:G→T:A or G:C (50%) | T | ||||
| 1,000,000 | 19 | C:G→any subst. (32%) | T | [ | |
| 617,354 | 12 | C:G→T:A (33%) | [ | ||
| C:G→G:C (25%) | T | ||||
| 533,482 | 14 | C:G→any subst. (93%) | NN | [ | |
| C:G→any subst. (36%) | NY | ||||
| 373,909 | 27 | C:G→T:A (30%) | [ | ||
| C:G→any subst. (11%) | T | ||||
| Lung cancer | tobacco smoke | C:G→A:T | none | [ | |
| arsenic exposure | T:A→G:C | none | [ | ||
| Melanoma | UV, APOBEC3A | C:G→T:A | pyrimidine dimers | [ | |
| unknown | G:C→any subst. | N | [ | ||
| Liver carcinoma | carcinogens | T:A→C:G | none | [ | |
| Leukemia | unknown | A:T→T:A | T | [ | |
| Endometrial cancer | POLEP286R | G:C→T:A | A | ||
N, any nucleotide; Y, C or T; R, A or G; D, A or G or T; H, A or C or T.
Figure 1(Top) Cytosine methylation and demethylation pathways; (Bottom) Products of cytosine and C5-substituted cytosine deamination.
Figure 2Conversion of isocitrate to α-ketoglutarate (α-KG) by isocitrate dehydrogenases (IDH) enzymes and conversion of α-KG to d-2-hydroxyglutarate (2-HG) by gain-of-function mutations in IDH1 or IDH2.
Rates of spontaneous deamination for cytosines.
| Deaminating base | Sequence context | Deaminated base product | Deamination rate at 37 °C ( | References |
|---|---|---|---|---|
| C | Free nucleoside | U | 9.4 ± 0.5 × 10−10 | [ |
| 3mC+ | Free nucleoside | 3mU | 5 × 10−7 | [ |
| 3mC+ | Free nucleotide | 3mU | 13 × 10−7 | [ |
| 5mC | Free nucleoside | T | 7.8 ± 0.3 × 10−10 | [ |
| 5hmC | Free nucleoside | 5hmU | 5.8 ± 0.8 × 10−10 | [ |
| 5fC | Free nucleoside | 5fU | 1.2 ± 0.2 × 10−9 | [ |
| 5caC | Free nucleoside | 5caU | not detected | [ |
| 5mCg( | Free nucleoside | Tg | 1.1 × 10−5 | [ |
| 5mCg( | Free nucleoside | Tg | 8.6 × 10−6 | [ |
| C | ssDNA | U | 2.1 × 10−10 | [ |
| C | ssDNA | U | ~1 × 10−10 | [ |
| 5mC | ssDNA | T | 9.5 × 10−10 | [ |
| C | dsDNA | U | 2.6 × 10−13 | [ |
| C | dsDNA | U | 4 × 10−13 | [ |
| C | dsDNA | U | ~7 × 10−13 | [ |
| 5mC | dsDNA | T | 5.8 × 10−13 | [ |
| 5mC | dsDNA | T | 1.5 × 10−11 | [ |
| 5mCg( | dsDNA | Tg | 5.2 × 10−6 | [ |
| 5mCg( | dsDNA | Tg | 7.0 × 10−6 | [ |
C, cytosine; 5mC, 5-methylcytosine; 3mC+, N3-methylcytosine; 5hmC, 5-hydroxymethylcytosine; 5fC, 5-formylcytosine; 5caC, 5-carboxycytosine; 5mCg(5S,6S) and 5mCg(5R,6R), 5-methylcytosine glycol stereoisomers; U, uracil; 3mU, N3-methyluracil; T, thymine; 5hmU, 5-hydroxymethyluracil; 5fU, 5-formyluracil; Tg, thymine glycols.
Figure 3(a) Numbering scheme for cytosines; (b) Pathways for the spontaneous deamination of C and 5mC (only 5mC is shown).
Figure 4Sequence context-dependent reaction products of 8-oxoG.
Figure 5(a) cis-trans stereoisomer pair of 5R thymine glycol; (b) cis-trans stereoisomer pair of 5S thymine glycol.
Figure 6(a) Canonical G:C base-pair; (b) Canonical A:T base-pair; (c) 8-oxoG(syn):A(anti) base-pair; (d) Gh:G base-pair; (e) Sp:G base-pair; (f) Iz:G base-pair; (g) Oz:G base-pair. For noncanonical base-pairs, the templating base is shown in blue.